The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy

Ischemic stroke remains the leading cause of neurologically based morbidity and mortality. Current stroke treatment is limited to two classes of FDA-approved drugs: thrombolytic agents (tissue plasminogen activator (tPA)) and antithrombotic agents (aspirin and heparin), which have a narrow time-wind...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mansoureh Barzegar, Karen Y. Stokes, Oleg Chernyshev, Roger E. Kelley, Jonathan S. Alexander
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ischemic stroke angiotensin converting enzyme-2 MasR therapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/06262237e529455088438a3d00021bc2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:06262237e529455088438a3d00021bc2
record_format	dspace
spelling	oai:doaj.org-article:06262237e529455088438a3d00021bc22021-11-25T16:50:33ZThe Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy10.3390/biomedicines91116672227-9059https://doaj.org/article/06262237e529455088438a3d00021bc22021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1667https://doaj.org/toc/2227-9059Ischemic stroke remains the leading cause of neurologically based morbidity and mortality. Current stroke treatment is limited to two classes of FDA-approved drugs: thrombolytic agents (tissue plasminogen activator (tPA)) and antithrombotic agents (aspirin and heparin), which have a narrow time-window (<4.5 h) for administration after onset of stroke symptoms. While thrombolytic agents restore perfusion, they carry serious risks for hemorrhage, and do not influence damage responses during reperfusion. Consequently, stroke therapies that can suppress deleterious effects of ischemic injury are desperately needed. Angiotensin converting enzyme-2 (ACE2) has been recently suggested to beneficially influence experimental stroke outcomes by converting the vasoconstrictor Ang II into the vasodilator Ang 1–7. In this review, we extensively discuss the protective functions of ACE2-Ang (1–7)-MasR axis of renin angiotensin system (RAS) in ischemic stroke.Mansoureh BarzegarKaren Y. StokesOleg ChernyshevRoger E. KelleyJonathan S. AlexanderMDPI AGarticleischemic strokeangiotensin converting enzyme-2MasRtherapyBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1667, p 1667 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ischemic stroke angiotensin converting enzyme-2 MasR therapy Biology (General) QH301-705.5
spellingShingle	ischemic stroke angiotensin converting enzyme-2 MasR therapy Biology (General) QH301-705.5 Mansoureh Barzegar Karen Y. Stokes Oleg Chernyshev Roger E. Kelley Jonathan S. Alexander The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
description	Ischemic stroke remains the leading cause of neurologically based morbidity and mortality. Current stroke treatment is limited to two classes of FDA-approved drugs: thrombolytic agents (tissue plasminogen activator (tPA)) and antithrombotic agents (aspirin and heparin), which have a narrow time-window (<4.5 h) for administration after onset of stroke symptoms. While thrombolytic agents restore perfusion, they carry serious risks for hemorrhage, and do not influence damage responses during reperfusion. Consequently, stroke therapies that can suppress deleterious effects of ischemic injury are desperately needed. Angiotensin converting enzyme-2 (ACE2) has been recently suggested to beneficially influence experimental stroke outcomes by converting the vasoconstrictor Ang II into the vasodilator Ang 1–7. In this review, we extensively discuss the protective functions of ACE2-Ang (1–7)-MasR axis of renin angiotensin system (RAS) in ischemic stroke.
format	article
author	Mansoureh Barzegar Karen Y. Stokes Oleg Chernyshev Roger E. Kelley Jonathan S. Alexander
author_facet	Mansoureh Barzegar Karen Y. Stokes Oleg Chernyshev Roger E. Kelley Jonathan S. Alexander
author_sort	Mansoureh Barzegar
title	The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
title_short	The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
title_full	The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
title_fullStr	The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
title_full_unstemmed	The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy
title_sort	role of the ace2/masr axis in ischemic stroke: new insights for therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/06262237e529455088438a3d00021bc2
work_keys_str_mv	AT mansourehbarzegar theroleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT karenystokes theroleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT olegchernyshev theroleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT rogerekelley theroleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT jonathansalexander theroleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT mansourehbarzegar roleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT karenystokes roleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT olegchernyshev roleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT rogerekelley roleoftheace2masraxisinischemicstrokenewinsightsfortherapy AT jonathansalexander roleoftheace2masraxisinischemicstrokenewinsightsfortherapy
_version_	1718412876333449216

The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy

Ejemplares similares